Halozyme Announces Takeda Received Regulatory Approval for Hyqvia® 10% Subcutaneous Injection Set With Enhanze® in Japan for Patients With Agammaglobulinemia or Hypogammaglobulinemia
Halozyme宣佈Takeda獲得日本監管機構批准，使用Enhanze®的Hyqvia® 10%皮下注射裝置，針對無免疫球蛋白血癥或低免疫球蛋白血癥患者。
